Licensing and Commercialization Agreement with Novartis Pharma AG (Tables)

12 Months Ended

Dec. 31, 2015

Licensing and Commercialization Agreement with Novartis Pharma AG

Schedule of collaboration revenue components

	Years ended December 31,
	2015		2014		2013
License revenue	$	38,083	$	38,373	$	—
Research and development activity revenue		8,378		2,000		—
API transfer revenue		5,020		883		—
Joint operating committee revenue		24		3		—
Total collaboration revenue	$	51,505	$	41,259	$	—